The therapeutic advantage of anlotinib for pancreatic cancer may lie in its effect on targeting the tumor microenvironment: 1Pancreatic stellate cells (PSCs), a major component of the tumor microenvironment (TME) of pancreatic cancer, expel a large number of extracellular matrix components, such as laminin, collagen, and fibronectin (24), inhibit the absorption of chemotherapeutic drugs and trigger drug resistance (25). The gene discussed is FN1; the disease is neoplasm.